XTX Topco Ltd Acquires Shares of 55,488 Revolution Medicines, Inc. (NASDAQ:RVMD)

Key Points

• XTX Topco Ltd has acquired 55,488 shares of Revolution Medicines, valued at approximately $1,962,000, as per their recent Form 13F filing.
• Analysts have a consensus rating of "Buy" for Revolution Medicines, with price targets ranging from $57.00 to $80.00, signaling strong future expectations.
• Revolution Medicines reported a loss of ($1.13) EPS in its last earnings release, slightly missing expectations and showing year-over-year deterioration.

XTX Topco Ltd bought a new position in shares of Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report) during the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 55,488 shares of the company's stock, valued at approximately $1,962,000.

Several other institutional investors and hedge funds have also recently modified their holdings of the business. Sterling Capital Management LLC grew its position in shares of Revolution Medicines by 588.7% in the fourth quarter. Sterling Capital Management LLC now owns 1,956 shares of the company's stock valued at $86,000 after purchasing an additional 1,672 shares in the last quarter. Kapitalo Investimentos Ltda purchased a new stake in shares of Revolution Medicines during the fourth quarter worth approximately $104,000. GF Fund Management CO. LTD. acquired a new stake in Revolution Medicines in the fourth quarter valued at $154,000. Goodman Advisory Group LLC acquired a new stake in Revolution Medicines during the first quarter worth approximately $127,000. Finally, Russell Investments Group Ltd. boosted its position in shares of Revolution Medicines by 11.4% in the 4th quarter. Russell Investments Group Ltd. now owns 4,243 shares of the company's stock valued at $186,000 after purchasing an additional 434 shares during the period. Hedge funds and other institutional investors own 94.34% of the company's stock.

Revolution Medicines Trading Up 0.2%

Shares of Revolution Medicines stock traded up $0.08 during trading hours on Monday, reaching $36.71. 423,319 shares of the company's stock were exchanged, compared to its average volume of 1,834,182. Revolution Medicines, Inc. has a 52-week low of $29.17 and a 52-week high of $62.40. The company has a fifty day moving average of $38.64 and a 200-day moving average of $38.88. The firm has a market capitalization of $6.84 billion, a price-to-earnings ratio of -9.17 and a beta of 1.16.

Revolution Medicines (NASDAQ:RVMD - Get Free Report) last released its earnings results on Wednesday, May 7th. The company reported ($1.13) earnings per share for the quarter, missing the consensus estimate of ($1.12) by ($0.01). During the same period in the previous year, the firm posted ($0.70) earnings per share. On average, equities research analysts anticipate that Revolution Medicines, Inc. will post -3.49 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on RVMD shares. HC Wainwright reissued a "buy" rating and issued a $72.00 price objective (down from $73.00) on shares of Revolution Medicines in a report on Wednesday, May 14th. Wedbush reiterated an "outperform" rating and set a $73.00 target price (up previously from $67.00) on shares of Revolution Medicines in a research note on Tuesday, June 24th. Oppenheimer boosted their price target on Revolution Medicines from $70.00 to $75.00 and gave the company an "outperform" rating in a research report on Thursday, May 8th. Guggenheim reiterated a "buy" rating and issued a $80.00 target price on shares of Revolution Medicines in a research note on Wednesday, June 25th. Finally, The Goldman Sachs Group assumed coverage on Revolution Medicines in a report on Tuesday, July 15th. They set a "buy" rating and a $65.00 price target for the company. Eleven research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Revolution Medicines has an average rating of "Buy" and an average price target of $68.91.

Revolution Medicines Company Profile

Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.